Syncope, a sudden, transient loss of consciousness and postural tone, is a phenomenon estimated to affect 30% to 40% of the population, and those numbers are likely underestimated given the high prevalence of patients who syncopize and do not present to a hospital or urgent care setting. Syncope is responsible for 740,000 trips to the emergency department and a quarter of a million hospital admissions each year in the United States alone. Causes of syncope range widely, including vasovagal, neurologic, metabolic, pulmonary, volume depletion, and cardiac. While the majority of syncopal events are innocuous, cardiac syncope is often indicative of a potentially fatal, underlying disease process, carrying a one-year mortality rate of 30%. Cardiac syncope occurs when the source of one's loss of consciousness stems from a problem in the heart that prevents it from supplying enough nutrients and oxygen to the brain. This cardiac problem may be a rhythm disturbance, a structural problem, or a structural problem that predisposes a patient to a rhythm disturbance. Cardiac syncope is estimated to be the cause of syncope in 15% of syncopal events. Distinguishing cardiac syncope from the myriad of other syncopal etiologies can be challenging. For this reason, it is imperative for all healthcare providers to have a general understanding of cardiac syncope and how to recognize it.
Syncope is caused by a temporary global failure of cerebral perfusion. When cardiac, the brain is not perfused because the heart is failing to generate enough cardiac output to send its freshly oxygenated blood to the brain. This is typically secondary to either a mechanical or structural cardiac defect or due to an arrhythmia that alters electrical conduction through the myocardium. Arrhythmias are recognized as the more common mechanism of the two. However, structural and mechanical abnormalities in the heart will often induce such arrhythmias. These processes are therefore often interrelated.
The following is a brief list of the more common etiologies of cardiac syncope. Further discussion regarding how to recognize and manage these etiologies will follow.
Syncope is a relatively common phenomenon, encountered among patients of every age range, race, religion, and socioeconomic status. Cardiovascular disease is the second most common cause of syncope, with arrhythmias being far more common than structural diseases. Ventricular tachycardia alone is responsible for 11% of syncopal events. Cardiovascular syncope overall is far more prevalent in the elderly population than the younger population, with 10% to 30% of syncopal events in patients over the age of 60 having a cardiac origin. Cardiovascular syncope is also more common in men than women.
Structural cardiac diseases are more prevalent among patients with comorbidities such as diabetes, hypertension, and hyperlipidemia, as well as among patients who smoke. Pre-excitation syndromes tend to be more common among women than men.
Brugada syndrome is more common among males and people of Southeast Asian descent.
All cases of cardiac syncope have the same general mechanism. When the heart fails to generate adequate cardiac output, the brain is inadequately perfused and temporarily malfunctions, leading to the syncopal event. Bradyarrhythmias lead to this final pathway because the heart is too slow to generate enough flow. Tachyarrhythmias force the heart to pump so fast that it lacks an adequate diastolic phase, leading to ineffective ventricular filling and reduced cardiac output.
Mechanical obstructions to blood flow and cardiac output will have similar effects but through multiple possible mechanisms. A chronic obstruction to forward blood flow out of the heart will lead to an increase in ventricular size and pressure. The increase in size leads to ventricular myocyte irritability, which can potentially induce arrhythmias. The increase in pressure can stimulate mechanoreceptors and induce a vagal response and secondary hypotension and bradycardia. This is in addition to the primary structural problem of the impeded forward blood flow. Obstructive pathologies, such as aortic stenosis, tumors, tamponade, and congenital hypertrophic cardiomyopathy can all follow this pathway, as can myocardial infarction and ischemia. Infarcted or ischemic ventricular tissue will have impaired contractility. Infarction of valves or chordae tendineae can lead to valve rupture, resulting in subsequent mechanical obstruction to forward flow or induction of retrograde blood flow. When cardiac tissue damage is present along the conduction system, conduction blocks and other arrhythmias can result. Aortic dissection can induce myocardial infarction when the dissection extends into the coronaries supplying vital portions of the myocardium. A leaking or ruptured aortic dissection can also diminish cardiac output through induction of hypovolemia or tamponade (if aortic contents extend into the pericardium). Pulmonary hypertension and pulmonary emboli will lead to a blockade of flow through the pulmonary artery and a reduction in left-sided preload and subsequent cardiac output in addition to the primary potential symptom of hypoxia.
Hypertrophic cardiomyopathy and arrhythmogenic right ventricular cardiomyopathy are two sources of cardiac syncope that are recognizable by specific histopathologic findings.
Hypertrophic cardiomyopathy is a myocardium disease in which a portion of the left ventricle asymmetrically hypertrophies, often in the septum. This leads to diminished left ventricular filling volume and contractility secondary to the stiffened, overgrown myocardium. The diminished left ventricular filling volume obstructs cardiac output, resulting in diminished blood flow to intramural coronary vessels and the rest of the body. The classic findings on myocardial biopsy of patients with hypertrophic cardiomyopathy are a thickened myocardium (often specifically in the septum) with disorganization of the myocyte fibers, myocardial scarring, and fibrosis along with narrowed vessels and dysplasia of the tunica media cells.
Arrhythmogenic Right Ventricular Cardiomyopathy
Arrhythmogenic right ventricular cardiomyopathy can be identified pathologically by fibrous tissue and fat cells replacing myocytes within the right ventricle. Patients with this condition will have dilated right ventricles and sometimes may have ventricular aneurysms. These can be particularly dangerous when located in the posterior basal, apical, or outflow tract portions of the heart.
When evaluating a syncopal patient to assess for a cardiac etiology, clinical history (when available) is one of the most useful diagnostic tools. Clinical history and physical exam alone have been found to identify an accurate diagnosis in 45% of patients who had a primary identifiable etiology of their syncope. Important aspects of the history that will lead to the determination of a cardiac etiology include older age (greater than 60 years), male sex, past medical history significant for any primary cardiac disease, coronary artery disease, valvular disease, or pulmonary emboli/pulmonary emboli risk factors (cancer, immobility, pregnancy, oral contraceptive pill use, etc). In addition, cardiovascular syncope will more commonly be associated with exertion, occur when supine, involve prodromal palpitations or chest pain, and lack prodromal vagal symptoms. Other key historical clues include a family history of arrhythmias; syncope; or early, unexplained death.
A careful physical exam will assess heart rate and rhythm. Any abnormalities will increase suspicion of a cardiac arrhythmia. In addition, an elevated respiratory rate or hypoxia will increase suspicion of a pulmonary embolism. Jugular venous distention and hypotension are suggestive signs of an obstructive mechanical cardiac etiology. Pathological cardiac murmurs, specifically new ones, will clue one into a valvular etiology, hypertrophic cardiomyopathy, or an obstructive intracardiac lesion. Muffled sounds can be heard with pericardial tamponade. Pedal edema or other evidence of deep venous thrombosis increase a patient's risk of pulmonary embolism.
When a syncopal event is identified as cardiac in origin, further workup should involve a 12 lead EKG, rhythm monitoring, and potential further studies such as an echocardiogram, implantable cardiac monitor, or Holter and/or stress test.
The EKG is a helpful tool for identifying arrhythmias. Sometimes it will diagnose active arrhythmias such as conduction block-induced bradycardias to less than 50 beats per minute, sinus pauses for more than 3 seconds, or nonsustained ventricular tachycardias. At other times it will demonstrate suggestive findings such as bifascicular blocks (either a full left bundle branch block or a right bundle branch block couples with a left anterior or left posterior fascicular block), QRS segments prolonged to greater than 120 milliseconds, Mobitz I second degree AV blocks, complete AV blocks, premature ventricular contraction QRS complexes, early repolarization, or Q waves which represent evidence of a preceding ischemic cardiac event resulting myocardial infarction. Electrocardiogram can also identify intrinsic conditions that predispose a patient to intermittent arrhythmias, such as Wolff-Parkinson-White syndrome (delta waves), Brugada syndrome (semi-right-bundle branch block and coved ST-segment elevation greater than 2 mm with inverted T waves in leads V1-V3), Long-QT syndrome (prolonged QT interval), hypertrophic cardiomyopathy (left atrial enlargement, left ventricular hypertrophy criteria possibly with dagger-shaped Q waves in inferolateral leads), and arrhythmogenic right ventricular cardiomyopathy (epsilon waves).
Basic lab tests, such as a complete blood count and basic metabolic panel, are frequently performed on patients presenting to an emergency department with syncope. However, these tests do not assist in predicting a cardiac etiology. Troponin, similarly, performs poorly as a diagnostic tool among syncopal patients. However, the natriuretic peptide, when measured among syncopal patients, has demonstrated utility in identifying patients with cardiac syncope and patients at risk of short-term major adverse cardiac events (sensitivity, 73%; specificity, 88%).
Once cardiac syncope is suspected, if no arrhythmia is identified, echocardiography is perhaps the most useful follow-up diagnostic test as it will directly identify structural abnormalities, as described above. In a retrospective study of 128 patients suspected of having cardiac syncope, the echocardiogram confirmed a diagnosis in 48% of patients, and 77% of patients who had a specific cardiac diagnosis. CT and MRI are also useful modalities in identifying structural cardiac pathologies, such as pulmonary emboli, cardiac masses, congenital heart disease, sarcoidosis, and arrhythmogenic right ventricular cardiomyopathy.
If cardiac syncope is not secondary to a mechanical problem and no arrhythmia is detected on initial EKG, stress testing and longer-term rhythm monitoring can be effective in catching the diagnosis. In cases of exertional syncope, exercise stress testing will often reveal the diagnosis. When symptoms are recurrent and frequent, a Holter monitor is recommended. If syncopal or pre-syncopal symptoms are recurrent but not frequent enough to be noted on the Holter monitor, an external loop recorder or implanted cardiac monitor can be used to generate a diagnosis.
The electrophysiologic study is another method that has been utilized to identify cases of cardiac syncope. This study involves the placement of catheter tips at multiple locations within the heart. Testing begins at the SA node and progresses throughout the remainder of the heart. During the study, the heart is paced and electric current is injected into various regions of the nonconducting endocardium and along the conduction pathway to attempt to reproduce an arrhythmia. Slow and/or fast pacing and proarrhythmic drugs may also be utilized for this purpose. When an arrhythmia occurs, this study allows the electrophysiologist to find the exact source of the irregular electrical activity and allows for the ablation of any misfiring cells. This procedure can thus be both diagnostic and therapeutic. Theoretically, this sounds like an excellent test. However, in practice, this test has poor sensitivity and specificity and is only recommended in patients with concurrent ischemic heart disease who would not otherwise receive an implanted cardiac defibrillator or in other high-risk patients in whom no other tests could reveal a diagnosis. Electrophysiologic studies are only considered diagnostic if they induce a sinus bradycardia with a prolonged sinus node recovery time of more than 525 milliseconds, a bundle branch block with tachycardia or a His-Purkinje block (second or third degree), sustained monomorphic ventricular tachycardia in a patient with preexisting cardiac infarction, or recurrent symptoms in the setting of rapid supraventricular tachycardia.
Treatment for cardiac syncope is offered to prevent the patient morbidity, physical injuries, and monetary costs of recurrent syncopal events and to prevent potential sudden cardiac death. The management of cardiac syncope varies widely and is essentially based on managing the specific condition which precipitated the syncopal event. The following is a general summary of management strategies; however, this is only a limited summary as the topic is vast.
Sinus node dysfunction
Sinus node abnormalities will typically lead to bradyarrhythmias. When a sinus bradycardia is noted, the first intervention should be an assessment for iatrogenic causes, such as medications with bradycardia as an intended or unintended effect. If such medications are in use and unnecessary to the patient, they should be terminated. Otherwise, pacemakers should be the next step sought out in management. Implantable dual chamber pacemakers are recommended to prevent future syncopal events. Implantation of a pacemaker should theoretically circumvent this outcome. However, there has not been a proven improvement in overall survival from this intervention, and 20% of these patients who receive pacemakers experience recurrent syncopal events.
Atrioventricular conduction system dysfunction
In cases of Mobitz type 2 second-degree or third-degree AV block, pacemaker implantation is helpful in preventing recurrence of syncope. Biventricular pacing modes are recommended in patients with coexisting heart failure, depressed left ventricular ejection fraction, or prolonged QRS segments noted on the electrocardiogram.
Implantable permanent pacemakers are recommended for patients with concerning histories and syncope in the setting of bifascicular or trifascicular bundle branch blocks.
Management of tachycardic sources of syncope is more complex, as many cases of tachycardic arrhythmias that precipitate syncope are self-limited. Supraventricular tachycardia can occur in patients with alternative atrioventricular nodal reentrant pathways. In such circumstances, catheter ablation of the alternative pathway is the best treatment modality. Medications are often utilized as a bridge to this definitive management if catheter ablation is not immediately possible. Management of atrial fibrillation should be first attempted conservatively with medication-based rate or rhythm control and then with ablation if such conservative therapy fails. Nonsustained ventricular tachycardia-induced syncope can be managed with beta blockers or calcium channel blockers. If this is insufficient, antiarrhythmic agents can be employed. Amiodarone is the first-line antiarrhythmic followed by class 1A and 1B antiarrhythmics. If syncopal events are frequent and unresponsive to medications, radiofrequency catheter ablation of the foci from which the tachycardia originates can be performed. In cases of ventricular tachycardia-induced syncope in the setting of underlying structural cardiac disease, patients may benefit from an implanted cardiac defibrillator. Although the placement of a cardiac defibrillator in such patients has been demonstrated to reduce the incidence of sudden cardiac death, these devices do not decrease patients risk of recurrent syncopal events or the resultant associated physical injuries and expenses.
Acquired QT Interval abnormalities: These are commonly iatrogenic due to medications that prolong the QT interval. In such circumstances, offending drug discontinuation is sufficient therapy.
Inherited Channelopathies: In cases such as long QT syndrome, Brugada syndrome, and other inherited causes of arrhythmogenic syncope, implantable cardiac defibrillators are the definitive management. The decision regarding when to implant these is patient- and circumstance-dependent.
Implanted pacemaker failure
A patient with an implanted pacemaker who presents to a hospital following a syncopal event should have the pacemaker interrogated by any available electrophysiologist. Syncope in the setting of pacemaker failure is usually the result of battery depletion, lead oversensing, or lead underpacing. Such problems can be managed with device or lead replacement.
The management of structural causes of syncope is specific to the structural problem. For example, In cases of aortic stenosis, aortic valve replacement is the definitive management. Atrial myxomas or other cardiac tumors should similarly be managed operatively. Heart failure or hypertrophic cardiomyopathy can be managed medically with nitrates and diuretics. Coronary artery disease can be managed with antiplatelet agents and anticoagulants. Acute coronary artery occlusion, when present, can be managed with revascularization techniques such as angioplasty or cardiac bypass surgery. Pulmonary emboli are managed with anticoagulants/thrombolytics. Any patient with an unknown specific etiology of syncope but a known structural cardiac disease can and should be evaluated for an implantable cardioverter-defibrillator.
All patients presenting with cardiac syncope who have not had a definitive intervention to prevent future events should be advised not to drive. Patients who have syncopized are 2 to 4 times more likely to be involved in motor vehicle collisions compared to the general population.
All patients presenting with a transient, apparent loss of consciousness should be assessed for the possibility of cardiac syncope. However, they could also have any of the many other causes of loss of consciousness. In cases of head trauma preceding loss of consciousness, a patient is considered to have had a concussion. Nontraumatic transient loss of consciousness can occur from other sources of syncope or non-syncopal events such as seizures; metabolic disturbances like hypoglycemia, hyponatremia, hypoxia, or hypocapnia); vertebrobasilar cerebral transient ischemic events; alcohol intoxication or other central nervous system depressant substance use; pseudoseizures; or psychogenic pseudosyncope. In these instances, loss of consciousness or presumed loss of consciousness is not due to global cerebral hypoperfusion as is the case in syncope. Among transient loss of consciousness events deemed to be syncopal, any event that results in a reduction of either cardiac output or peripheral vascular resistance can result in this common outcome.
The following are several noncardiac etiologies:
Patients with easily treatable etiologies of cardiac syncope will generally have a good prognosis with adequate treatment. Patients with advanced heart failure and syncope, however, have a 45%, one-year mortality. Patients with cardiac syncope are also more likely to have recurrent syncopal events with an estimated recurrence rate of 33% within 3 years. Recurrent syncope can worsen a patients quality of life, especially if syncopal events result in broken bones, intracranial bleeds, or other traumatic injuries.
Although the treatment and diagnostic modalities employed in the management of cardiac syncope are largely targeted at preventing a future sudden cardiac death, syncopal events can have immediate complications as well. These complications include costs of hospitalizations, treatment, and lost work time as well as physical injuries related to falling during the syncopal event.
Cardiac syncope is often first identified by the primary care provider, nurse practitioner, emergency department physician or internist. Because the treatment of cardiac syncope does vary it is important to refer the patient to the cardiologist for definitive workup. Treatment for cardiac syncope is offered to prevent the patient morbidity, physical injuries, and monetary costs of recurrent syncopal events and to prevent potential sudden cardiac death. The management of cardiac syncope varies widely and is essentially based on managing the specific condition which precipitated the syncopal event.
The outcomes of patients with a treatable cause of cardiac syncope are good. Patients with advanced heart failure and syncope, however, have a 45%, one-year mortality. Patients with cardiac syncope are also more likely to have recurrent syncopal events with an estimated recurrence rate of 33% within 3 years. Recurrent syncope can worsen a patients quality of life, especially if syncopal events result in broken bones, intracranial bleeds, or other traumatic injuries.
|||Seger JJ, Syncope evaluation and management. Texas Heart Institute journal. 2005 [PubMed PMID: 16107115]|
|||Guimarães RB,Essebag V,Furlanetto M,Yanez JPG,Farina MG,Garcia D,Almeida ED,Stephan L,Lima GG,Leiria TLL, Structural heart disease as the cause of syncope. Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas. 2018 Mar 1 [PubMed PMID: 29513795]|
|||Nishijima DK,Lin AL,Weiss RE,Yagapen AN,Malveau SE,Adler DH,Bastani A,Baugh CW,Caterino JM,Clark CL,Diercks DB,Hollander JE,Nicks BA,Shah MN,Stiffler KA,Storrow AB,Wilber ST,Sun BC, ECG Predictors of Cardiac Arrhythmias in Older Adults With Syncope. Annals of emergency medicine. 2018 Apr [PubMed PMID: 29275946]|
|||Waytz J,Cifu AS,Stern SDC, Evaluation and Management of Patients With Syncope. JAMA. 2018 Jun 5 [PubMed PMID: 29872846]|
|||Anderson J,O'Callaghan P, Cardiac syncope. Epilepsia. 2012 Dec [PubMed PMID: 23153208]|
|||Arthur W,Kaye GC, The pathophysiology of common causes of syncope. Postgraduate medical journal. 2000 Dec [PubMed PMID: 11085764]|
|||Ceresnak SR,Dubin AM, Wolff-Parkinson-White syndrome (WPW) and athletes: Darwin at play? Journal of electrocardiology. 2015 May-Jun [PubMed PMID: 25722079]|
|||Vettor G,Zorzi A,Basso C,Thiene G,Corrado D, Syncope as a Warning Symptom of Sudden Cardiac Death in Athletes. Cardiology clinics. 2015 Aug [PubMed PMID: 26115828]|
|||Linzer M,Yang EH,Estes NA 3rd,Wang P,Vorperian VR,Kapoor WN, Diagnosing syncope. Part 1: Value of history, physical examination, and electrocardiography. Clinical Efficacy Assessment Project of the American College of Physicians. Annals of internal medicine. 1997 Jun 15 [PubMed PMID: 9182479]|
|||Shen WK,Sheldon RS,Benditt DG,Cohen MI,Forman DE,Goldberger ZD,Grubb BP,Hamdan MH,Krahn AD,Link MS,Olshansky B,Raj SR,Sandhu RK,Sorajja D,Sun BC,Yancy CW, 2017 ACC/AHA/HRS Guideline for the Evaluation and Management of Patients With Syncope: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. Journal of the American College of Cardiology. 2017 Aug 1 [PubMed PMID: 28286221]|
|||Thiruganasambandamoorthy V,Ramaekers R,Rahman MO,Stiell IG,Sikora L,Kelly SL,Christ M,Claret PG,Reed MJ, Prognostic value of cardiac biomarkers in the risk stratification of syncope: a systematic review. Internal and emergency medicine. 2015 Dec [PubMed PMID: 26498335]|
|||Tanimoto K,Yukiiri K,Mizushige K,Takagi Y,Masugata H,Shinomiya K,Hosomi N,Takahashi T,Ohmori K,Kohno M, Usefulness of brain natriuretic peptide as a marker for separating cardiac and noncardiac causes of syncope. The American journal of cardiology. 2004 Jan 15 [PubMed PMID: 14715356]|
|||Recchia D,Barzilai B, Echocardiography in the evaluation of patients with syncope. Journal of general internal medicine. 1995 Dec [PubMed PMID: 8770716]|
|||Tandri H,Calkins H, MR and CT imaging of Arrhythmogenic Cardiomyopathy. Cardiac electrophysiology clinics. 2011 Jun 1 [PubMed PMID: 21552378]|
|||Sparrow PJ,Merchant N,Provost YL,Doyle DJ,Nguyen ET,Paul NS, CT and MR imaging findings in patients with acquired heart disease at risk for sudden cardiac death. Radiographics : a review publication of the Radiological Society of North America, Inc. 2009 May-Jun [PubMed PMID: 19448117]|
|||Kapoor WN, Evaluation and outcome of patients with syncope. Medicine. 1990 May [PubMed PMID: 2189056]|
|||Moya A,Sutton R,Ammirati F,Blanc JJ,Brignole M,Dahm JB,Deharo JC,Gajek J,Gjesdal K,Krahn A,Massin M,Pepi M,Pezawas T,Ruiz Granell R,Sarasin F,Ungar A,van Dijk JG,Walma EP,Wieling W, Guidelines for the diagnosis and management of syncope (version 2009). European heart journal. 2009 Nov [PubMed PMID: 19713422]|
|||Epstein AE,DiMarco JP,Ellenbogen KA,Estes NA 3rd,Freedman RA,Gettes LS,Gillinov AM,Gregoratos G,Hammill SC,Hayes DL,Hlatky MA,Newby LK,Page RL,Schoenfeld MH,Silka MJ,Stevenson LW,Sweeney MO,Tracy CM,Epstein AE,Darbar D,DiMarco JP,Dunbar SB,Estes NA 3rd,Ferguson TB Jr,Hammill SC,Karasik PE,Link MS,Marine JE,Schoenfeld MH,Shanker AJ,Silka MJ,Stevenson LW,Stevenson WG,Varosy PD, 2012 ACCF/AHA/HRS focused update incorporated into the ACCF/AHA/HRS 2008 guidelines for device-based therapy of cardiac rhythm abnormalities: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. Journal of the American College of Cardiology. 2013 Jan 22 [PubMed PMID: 23265327]|
|||Sgarbossa EB,Pinski SL,Jaeger FJ,Trohman RG,Maloney JD, Incidence and predictors of syncope in paced patients with sick sinus syndrome. Pacing and clinical electrophysiology : PACE. 1992 Nov [PubMed PMID: 1279599]|